Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LYRA 
Lyra Therapeutics Inc (LYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: LYRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.86% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.91M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 873483 | Beta -0.18 | 52 Weeks Range 0.11 - 5.77 | Updated Date 04/2/2025 |
52 Weeks Range 0.11 - 5.77 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Earnings Date
Report Date 2025-03-19 | When Before Market | Estimate -0.13 | Actual -0.1419 |
Profitability
Profit Margin - | Operating Margin (TTM) -4672.73% |
Management Effectiveness
Return on Assets (TTM) -36.33% | Return on Equity (TTM) -184.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2150067 | Price to Sales(TTM) 5.16 |
Enterprise Value 2150067 | Price to Sales(TTM) 5.16 | ||
Enterprise Value to Revenue 1.4 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 65880600 | Shares Floating 46902348 |
Shares Outstanding 65880600 | Shares Floating 46902348 | ||
Percent Insiders 0.42 | Percent Institutions 50.86 |
Analyst Ratings
Rating 3 | Target Price 1.25 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Lyra Therapeutics Inc
Company Overview
History and Background
Lyra Therapeutics, founded in 2003, is a clinical-stage biopharmaceutical company focused on developing innovative ENT therapies. It initially focused on ear, nose, and throat disorders. The company has evolved to focus on chronic rhinosinusitis (CRS).
Core Business Areas
- ENT Therapies: Develops and commercializes therapies for ear, nose, and throat (ENT) disorders, primarily chronic rhinosinusitis (CRS).
Leadership and Structure
The leadership team consists of experienced professionals in pharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- LYR-220: LYR-220 is a bioresorbable nasal implant designed to deliver mometasone furoate directly to the sinuses for up to six months for the treatment of CRS. The product is currently in clinical trials. Competitors include traditional nasal sprays and other surgical and non-surgical interventions for CRS.
- LYR-210: LYR-210 is a bioresorbable nasal implant designed to deliver mometasone furoate directly to the sinuses for up to six months for the treatment of CRS. Development was discontinued in favor of LYR-220. Competitors included traditional nasal sprays and other surgical and non-surgical interventions for CRS.
Market Dynamics
Industry Overview
The ENT therapeutics market is growing, driven by an aging population, increasing prevalence of chronic diseases, and advancements in treatment options.
Positioning
Lyra Therapeutics aims to differentiate itself through its innovative bioresorbable implant technology for localized drug delivery in the sinuses. It seeks to provide a more effective and convenient treatment option for CRS compared to existing therapies.
Total Addressable Market (TAM)
The CRS market is estimated to be multi-billion dollar market globally. Lyra is position to capture a percentage of the non-surgical CRS market if LYR-220 achieves FDA approval and is commercially successful.
Upturn SWOT Analysis
Strengths
- Innovative bioresorbable implant technology
- Targeted drug delivery for enhanced efficacy
- Potential for reduced systemic side effects
- Focus on unmet needs in ENT disorders
Weaknesses
- Limited commercialized products
- Dependence on clinical trial success
- High development costs
- Relatively small company size
Opportunities
- Expansion into new ENT indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Growing awareness of CRS and need for better treatments
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Unfavorable clinical trial outcomes
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- SNY
- REGN
Competitive Landscape
Lyra faces competition from established players with marketed products for CRS. Its advantage lies in its novel drug delivery technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by progress in clinical trials and securing funding.
Future Projections: Future growth depends on the successful development and commercialization of LYR-220. Analyst estimates vary based on the perceived probability of success.
Recent Initiatives: Focusing on the clinical development of LYR-220 and seeking strategic partnerships to support commercialization efforts.
Summary
Lyra Therapeutics is a clinical-stage biopharmaceutical company with a focus on ENT disorders, particularly CRS. Its strengths lie in its innovative drug delivery technology and targeted approach. Its challenges include dependence on clinical trial success and competition from larger pharmaceutical companies. The company's future depends on the successful development and commercialization of LYR-220.
Similar Companies
REGN
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Lyra Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyra Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-05-01 | CEO, President & Director Dr. Maria Palasis Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://lyratherapeutics.com |
Full time employees 30 | Website https://lyratherapeutics.com | ||
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.